The B-Cell Lymphoma Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of B-Cell Lymphoma treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the B-Cell Lymphoma pipeline landscape and fostering the potential growth of B-Cell Lymphoma therapeutic advancements.

 

Key Takeaways from the B-Cell Lymphoma Pipeline Report

• DelveInsight’s B-Cell Lymphoma pipeline report depicts a robust space with 160+ active players working to develop 170+ pipeline therapies for B-Cell Lymphoma treatment.
• The leading companies working in the B-Cell Lymphoma market include Oncternal Therapeutics, Inc., ZAI Lab, Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme LLC, Sanofi, InnoCare Pharma, Allogene Therapeutics, Cellular Biomedicine Group Ltd., Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation, Fundamenta Therapeutics, Ltd., Juventas Cell Therapy, Shanghai Hengrui Pharmaceutical Co., Ltd., Guangzhou Lupeng Pharmaceutical Company LTD., TG Therapeutics Inc., Roche, 2seventy bio, AstraZeneca, Nektar Therapeutics, ADC Therapeutics, Genor Biopharma, Pacylex Pharmaceuticals, Antengene Corporation, Zhejiang DTRM Biopharma, Shanghai Cell Therapy Group Co., Ltd., Nanjing Legend Biotech Co., and others.
• Promising B-Cell Lymphoma Pipeline Therapies in the various stages of development include Epcoritamab, Cyclophosphamide, Rituximab, Lenalidomide, GNC-038, Tafasitamab, Bendamustine, Maplirpacept, and others.
• On September 2023, AbbVie announced a study of Phase 3 Clinical Trials for Epcoritamab, Cyclophosphamide, Rituximab and Vincristine. In the Arm 1, participants will receive subcutaneous epcoritamab combined with intravenous and oral R-CHOP followed by subcutaneous epcoritamab in 21-day cycles. In the Arm 2, participants will receive intravenous and oral R-CHOP followed by intravenous rituximab in 21-day cycles.
• On September 2023, Genmab announced a study of Phase 2 Clinical Trials for Epcoritamab and Lenalidomide. The purpose of the study is to examine efficacy and safety of epcoritamab with and without lenalidomide in newly diagnosed elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL) who cannot tolerate anthracycline therapy. Epcoritamab (also known as EPKINLY™, GEN3013 and DuoBody®-CD3xCD20) is an antibody that has already been tested in several clinical studies.

 

Request a sample and discover the recent advances in B-Cell Lymphoma Treatment Drugs @ B-Cell Lymphoma Pipeline Report

 

The B-Cell Lymphoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage B-Cell Lymphoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the B-Cell Lymphoma clinical trial landscape.

 

B-Cell Lymphoma Overview

B-cell lymphoma is a type of non-Hodgkin lymphoma that originates in the B-cells. It is the most common type of lymphoma and about 85% of all lymphomas in the United States are B-cell. Common symptoms associated with lymphoma include painless enlargement of one or more lymph node areas, fever, night sweats, and weight loss.

 

Find out more about B-Cell Lymphoma Treatment Drugs @ Drugs for B-Cell Lymphoma Treatment

 

B-Cell Lymphoma Emerging Drugs Profile

• Odronextamab: ZAI Lab
• NKTR-255: Nektar Therapeutics
• Zilovertamab Vedotin: Merck Sharp & Dohme LLC
• Abexinostat: Xynomic Pharmaceuticals

 

B-Cell Lymphoma Pipeline Therapeutics Assessment

The B-Cell Lymphoma pipeline report proffers an integral view of the A B-Cell Lymphoma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

 

Learn more about the emerging B-Cell Lymphoma Pipeline Therapies @ B-Cell Lymphoma Clinical Trials Assessment

 

Scope of the B-Cell Lymphoma Pipeline Report

• Coverage- Global
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Companies- Oncternal Therapeutics, Inc., ZAI Lab, Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme LLC, Sanofi, InnoCare Pharma, Allogene Therapeutics, Cellular Biomedicine Group Ltd., Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation, Fundamenta Therapeutics, Ltd., Juventas Cell Therapy, Shanghai Hengrui Pharmaceutical Co., Ltd., Guangzhou Lupeng Pharmaceutical Company LTD., TG Therapeutics Inc., Roche, 2seventy bio, AstraZeneca, Nektar Therapeutics, ADC Therapeutics, Genor Biopharma, Pacylex Pharmaceuticals, Antengene Corporation, Zhejiang DTRM Biopharma, Shanghai Cell Therapy Group Co., Ltd., Nanjing Legend Biotech Co., and others
• Pipeline Therapies- Epcoritamab, Cyclophosphamide, Rituximab, Lenalidomide, GNC-038, Tafasitamab, Bendamustine, Maplirpacept, and others.

 

Dive deep into rich insights for new drugs for B-Cell Lymphoma Treatment, Visit @ B-Cell Lymphoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. B-Cell Lymphoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. B-Cell Lymphoma – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Odronextamab: ZAI Lab
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Abexinostat: Xynomic Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. TG 1801: TG Therapeutics Inc.
15. Drug profiles in the detailed report…..
16. Inactive Products
17. B-Cell Lymphoma Key Companies
18. B-Cell Lymphoma Key Products
19. B-Cell Lymphoma- Unmet Needs
20. B-Cell Lymphoma- Market Drivers and Barriers
21. B-Cell Lymphoma- Future Perspectives and Conclusion
22. B-Cell Lymphoma Analyst Views
23. B-Cell Lymphoma Key Companies
24. Appendix

 

For further information on the B-Cell Lymphoma Pipeline therapeutics, reach out to B-Cell Lymphoma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting